-
Document de presse | 2018.06.19
In-Cell-Art, the Institut Pasteur and BioNet-Asia announce the collaborative development of a dengue vaccine candidate
In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies, BioNet-Asia (BNA), an innovative vaccine developer, and the research team led by Dr. Anavaj Sakuntabhai at the Functional Genetics of Infectious Diseases Unit, Institut Pasteur Paris France, (GFMI-IP), announce today the development of Nanotaxi® formulated DNA vaccine to induce strong immune response against...
-
Document de presse | 2021.01.19
COVID-19: a lentiviral vaccine candidate for intranasal administration provides sterilizing protection in animal models
Scientists from the Institut Pasteur-TheraVectys Joint Laboratory recently published in Cell Host & Microbe1 the results of tests, in two preclinical models, of a COVID-19 vaccine candidate using a lentiviral vector administered by nasal route. Their study demonstrates that the vaccine candidate induces antibody response with strong neutralizing activity against SARS-CoV-2, as well as...
-
Document de presse | 2023.09.19
Development of an onco-therapeutic vaccine candidate against human papillomavirus (HPV)-induced cancers, based on preclinical results showing 100% efficacy
The Biotech TheraVectys, in collaboration with Institut Pasteur-TheraVectys Joint Laboratory, has just demonstrated the preclinical efficacy of its "Lenti-HPV-07" lentiviral vector-based vaccine candidate, administered intramuscularly, against cervical and oropharyngeal cancers induced by human papillomavirus (HPV). These results were published in EMBO Molecular Medicine journal on September 7,...
-
Document de presse | 2025.12.22
Building a better vaccine: Study is first to ID expanded, role of flu antibodies in preventing transmission
Findings suggest future vaccines use natural antibodies to target both infection and spread.Today’s influenza vaccines primarily prevent infection in individuals, but new research led by the University of Michigan and the Institut Pasteur suggests that incorporating antibodies generated after infection could lead to more powerful vaccines by also reducing person-to-person transmission.The...
-
Document de presse | 2026.01.28
Institut Pasteur statement on U.S. administration's attacks against biomedical research, global public health action and vaccination
For several months now, the current U.S. administration has consistently attacked and endeavored to weaken biomedical research and public health action in the United States and worldwide with unparalleled vigor. This situation has many consequences – both ethical and economic – but above all it is a grave attack on healthcare protection, and an unprecedented assault on the systems and...
-
Document de presse | 2021.07.16
ComCor study: analysis of the effectiveness of messenger RNA vaccines against the SARS-CoV-2 Alpha and Beta variants in France
Over the past six months, the World Health Organization has categorized four SARS-CoV-2 variants as being "of concern" because they are more transmissible or may escape the immune response. They have been termed the Alpha, Beta, Gamma and Delta variants. Scientists from the Institut Pasteur, in collaboration with the French National Health Insurance Fund (CNAM), Ipsos and Santé publique France,...
-
Document de presse | 2021.09.21
Covid-19: study on the effectiveness of immune memory after mRNA vaccination to recognize variants of SARS-CoV-2
The teams from Henri-Mondor AP-HP hospital and Paris-Est Créteil University, Inserm, CNRS, University of Paris, within the Necker-Enfants Malades Institute, and the Institut Pasteur analyzed the capacity of the immune memory generated after mRNA vaccination to recognize and neutralize SARS-CoV-2 variants.This work, coordinated by Prof. Matthieu Mahévas, Dr Claude-Agnès Reynaud, Prof. Jean-Claude...
-
Document de presse | 2020.04.16
Bill & Melinda Gates Medical Research Institute and the Institut Pasteur to Develop a Novel Vaccine Against Shigella
The Bill & Melinda Gates Medical Research Institute (Gates MRI) and the Institut Pasteur have entered into an exclusive collaboration and license agreement to jointly develop a quadrivalent synthetic carbohydrate-based conjugate vaccine against Shigella flexneri serotypes 2a, 3a, and 6 and Shigella sonnei. Gates MRI will have an exclusive license for manufacture and commercialization of...
-
Document de presse | 2021.10.26
The intranasal lentiviral vaccine candidate (Lenti-S) protects brain and lung in a pre-clinical animal model
The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, primarily targets the respiratory tract, but its ability to infect cells of the nervous system has also been largely reported. Indeed, the expression of the receptor of this virus, the Angiotensin Converting Enzyme 2 (ACE2), by neuronal and glial cells makes the brain susceptible to SARS-CoV-2. Moreover, neurological manifestations are...
-
Document de presse | 2021.11.26
ComCor study: new results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
From May 23 to August 13, 2021, the Institut Pasteur, in partnership with the French National Health Insurance Fund (CNAM), Santé publique France and the Ipsos institute, conducted the fourth part of the ComCor epidemiological study on circumstances and places of infection with the SARS-CoV-2 virus in France. The aim of the study was to identify the socio-demographic factors, places visited and...